1. Home
  2. SHLS vs TNDM Comparison

SHLS vs TNDM Comparison

Compare SHLS & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shoals Technologies Group Inc.

SHLS

Shoals Technologies Group Inc.

N/A

Current Price

$8.11

Market Cap

1.3B

Sector

Technology

ML Signal

N/A

Logo Tandem Diabetes Care Inc.

TNDM

Tandem Diabetes Care Inc.

N/A

Current Price

$17.84

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SHLS
TNDM
Founded
1996
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
SHLS
TNDM
Price
$8.11
$17.84
Analyst Decision
Buy
Buy
Analyst Count
14
25
Target Price
$11.39
★ $26.90
AVG Volume (30 Days)
★ 7.0M
2.4M
Earning Date
11-04-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 42.86
N/A
EPS
★ 0.17
N/A
Revenue
$475,331,000.00
★ $1,014,736,000.00
Revenue This Year
$41.01
$6.14
Revenue Next Year
$7.37
$8.10
P/E Ratio
$51.32
★ N/A
Revenue Growth
★ 19.07
7.93
52 Week Low
$5.55
$12.26
52 Week High
$13.18
$29.65

Technical Indicators

Market Signals
Indicator
SHLS
TNDM
Relative Strength Index (RSI) 49.82 49.47
Support Level $7.84 $17.61
Resistance Level $8.54 $18.13
Average True Range (ATR) 0.80 1.34
MACD 0.05 -0.02
Stochastic Oscillator 35.34 49.69

Price Performance

Historical Comparison
SHLS
TNDM

About SHLS Shoals Technologies Group Inc.

Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.

About TNDM Tandem Diabetes Care Inc.

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.

Share on Social Networks: